MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers

Merck & Co., Inc. (MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing authorization of its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for two types of gynecologic cancers.The first indication involves Keytruda in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the first-line treatment of adult patients with primary advanced or recur ...